



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Product Information

| | |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Description: | Recombinant human PCSK9 (Human proprotein convertase subtilisin/kexin 9) encompassing amino acids 31-692, which comprise the protodomain, the catalytic, and the C-terminal domains. The construct contains a C-terminal His-tag (6xHis) followed by an Avi-tag™. The protein contains the potent gain of function D374Y mutation. The protein was affinity purified. |
| Background: | PCSK9 (Proprotein convertase subtilisin/kexin type 9) functions as a negative regulator of hepatic low-density lipoprotein receptors (LDLRs) by binding to the LDLR ectodomain. The D374Y mutation is a gain of function mutation. The D374Y mutation is associated with hypercholesterolemia. This PCSK9 mutant is more potent at decreasing LDL uptake than wild-type PCSK9, most likely by increasing the binding affinity of PCSK9 for the LDLR. A deeper understanding of the function of this mutant protein and development of specific inhibitors may result in new therapeutic approaches for PCSK9 D374Y-linked diseases. |
| Species: | Human |
| Construct: | PCSK9 (D374Y) (31-692(end)-His-Avi)(Biotin) |
| Mutation: | D374Y |
| Concentration: | 0.44 mg/ml |
| Expression System: | HEK293 |
| Purity: | ≥90% |
| Format: | Aqueous buffer solution. |
| Formulated In: | 8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol |
| MW: | Pro: 14 kDa; Mature: 60 kDa + glycans |
| Glycosylation: | This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
| Genbank Accession: | NM_174936 |
| Label: | This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation was confirmed to be ≥90%. |
| Stability: | At least 6 months at -80°C. |
| Storage: | -80°C |
| Instructions for Use: | Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles. |
| Applications: | SDS-PAGE and pull-down assays. |

Quality Control Data

4-20% SDS-PAGE Coomassie Staining



Biotin-Avidin Pulldown

